Sign in

    Kevin A. Lobo

    Chair, Chief Executive Officer, and President at Stryker Corp
    Board
    Since 2021
    Age
    59 years
    Tenure
    Joined SYK in 2011 as an executive officer and Group President of Stryker Orthopaedics, then promoted to Chief Executive Officer and President in 2012, became Chair in 2014, served as both Chair and CEO from 2018 to 2021, and resumed the role of President in 2021.

    Also at Stryker Corp

    GSB
    Glenn S. Boehnlein
    Vice President, Chief Financial Officer (until April 1, 2025)
    JAP
    J. Andrew Pierce
    Group President, MedSurg and Neurotechnology
    MKF
    M. Kathryn Fink
    Vice President, Chief Human Resources Officer

    About

    Kevin A. Lobo is a seasoned leader in the medical technology industry with 59 years of life experience, hailing from the United States. He has built a solid reputation for steering Stryker Corporation through multiple leadership roles while demonstrating a commitment to innovation and growth.

    He began his journey at SYK in 2011 as an executive officer and Group President of Stryker Orthopaedics, rapidly ascending the corporate ladder. In 2012, he took on the dual roles of Chief Executive Officer and President, followed by his appointment as Chair in 2014, reflecting a series of impactful promotions that solidified his influence within the company.

    Beyond his core roles at SYK, he has extended his expertise to other prominent organizations, holding directorships at The Advanced Medical Technology Association and Parker-Hannifin Corporation, and serving as Chair of the Valley Health System Board of Trustees. His multifaceted career highlights a blend of strong corporate governance and strategic vision in both his professional and community engagements.

    $SYK Performance Under Kevin A. Lobo

    Past Roles

    OrganizationRoleDate RangeDetails
    Stryker Corporation Group President, Stryker Orthopaedics 2011-2012 Held position prior to promotion to CEO and President
    Johnson & Johnson Various Leadership Roles 2003-2011 Held multiple leadership roles before joining Stryker

    External Roles

    OrganizationRoleDate Range
    The Advanced Medical Technology Association (AdvaMed) Director N/A
    Parker-Hannifin Corporation Director N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,400,000Annual3.7% increase vs 2022
    Actual Salary Paid$1,391,667As PaidReported in the Salary column
    Deferred ContributionsN/ADeferredPortion deferred into 401(k) and Supplemental Plan

    Performance Compensation

    Data from  FY 2023

    Bonus Plan - Core Performance Metrics

    MetricWeightThresholdTargetActual PerformanceDetails
    Adjusted Operating Income20%$4.266B $4.788B $4.972B Basis for 20% payout calculation
    Adjusted Operating Income Margin20%23.66% 23.96% 24.28% Margin improvement
    Constant Currency Sales40%$18.793B $19.783B $20.480B Sales growth metric
    Free Cash Flow Excluding Recall Payments20%$2.326B $2.764B $3.172B Cash flow performance

    Bonus Plan - Overachievement Bonus Metrics

    MetricWeightTargetActual PerformanceDetails
    Adjusted Operating Income20%$4.932B $4.972B Additional bonus component
    Constant Currency Sales30%$20.178B $20.480B Additional bonus component
    Free Cash Flow Excluding Recall Payments20%$2.931B $3.172B Additional bonus component
    Adjusted Net Earnings Per Diluted Share30%$10.29 $10.60 Earnings performance metric

    Modifier: Potential bonus payout adjustment of +/-10% based on progress toward CR commitments.

    Non-Equity Incentive Plan Compensation

    MetricAmountDetails
    Target Bonus$2,100,000 Set as the target bonus
    Maximum Bonus$4,200,000 Maximum payout opportunity (up to an additional 100% of target)
    Actual Bonus Payment$3,780,000 Represents 180% of the target bonus
    Operating Income Minimum$3.79B Minimum adjusted consolidated operating income required before bonus accrual
    Modifier+/-10% Adjustment based on CR commitments (carbon emissions & diversity, equity & inclusion)

    Performance Stock Units (PSUs)

    MetricValueDetails
    Grant DateFeb 9, 2023 Performance period: 2023–2025
    Threshold12,582 units Minimum performance level
    Target25,166 units Performance target
    Maximum50,332 units 200% of target
    Grant Date Fair Value$6,652,884 Based on the target outcome
    Vesting DateMar 21, 2026 Vesting contingent on achieving performance goals
    ConditionsN/AMinimum adjusted net earnings per diluted share required

    Option Awards

    MetricValueDetails
    Grant DateFeb 9, 2023 Options are time-based and not tied to performance metrics
    Number of Options Granted100,665
    Exercise Price$268.22/share
    Grant Date Stock Price$264.36/share
    Grant Date Fair Value$8,410,645 Valued using the Black-Scholes model
    Vesting Schedule20% per year for 5 years 20% vesting on each anniversary of the grant date
    Option ExpirationFeb 8, 2033 10-year term